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Abstract
Background: Quality of near end-of-life (EOL) care is typically evaluated using six accepted quality indicators (QIs).
Research has yet to evaluate the quality of EOL care for liver cancer patients in Taiwan. We evaluated the effect of
hospice care on the quality of EOL care for patients with advanced liver cancer.
Methods: Using claims data obtained from the Taiwan National Health Insurance Research Database, we analyzed
the QIs of EOL care for patients who died between 2000 and 2011. Logistic regression was performed to identify
predictors for QIs of EOL care.
Results: A total of 3092 adult patients died of liver cancer during the study period. The patients were divided into
those who received hospice care for a period longer than 1 month (long-H group), shorter than 1 month (short-H
group), and not at all (non-H group). There was no significant difference in survival probability among the three
groups (p = 0.212). Compared with the non-H group, the long- and short-H groups exhibited a significantly lower
risk of being admitted to an intensive care unit (ICU) (odds ratios [ORs] = 0.25 and 0.26, respectively, p < 0.001) and
requiring cardiopulmonary resuscitation (CPR) during the final month of life (ORs = 0.21 and 0.09, respectively, p < 0.001).
Compared with the non-H group, the short-H group had a higher risk of more than one emergency room (ER) visit, and
more than one hospital admission (OR = 1.97, p = 0.003; and OR = 1.56, p = 0.001, respectively), but the long-H group did
not differed significantly from the non-H group on these measures.
Conclusions: Patients with liver cancer who received hospice care were less likely to be admitted to ICUs or require CPR
compared with those who received no hospice care. A longer duration of hospice care was associated with reduced
risks of more than one ER visit and more than one hospital admission. We conclude that EOL cancer care in Taiwan
might be improved by implementing policies encouraging early hospice referral programs.
Background
Cancer, a leading cause of death worldwide, accounted
for 8.2 million deaths in 2012 [1]. Although the diagnos-
tic practices and treatments for cancers have improved,
the mortality rate from this disease has not [2, 3]. In
Taiwan, 43,665 (28.4 %) of the people who died in 2012
died from cancer [4]. Because of the high mortality rate,
a complete cancer treatment program requires a consid-
eration of the quality of near end-of-life (EOL) care.
Six quality indicators (QIs) of EOL cancer care have been
accepted and validated: (1) receiving chemotherapy during
the final 2 weeks of life, (2) having more than one emer-
gency room (ER) visit, (3) being admitted to a hospital
more than once, (4) receiving care in an intensive care unit
(ICU) during the final month of life, (5) receiving cardio-
pulmonary resuscitation (CPR) during the final month of
life, and (6) dying in an acute care hospital [5, 6]. These six
QIs of EOL care have been adopted in the United States
[5, 7], Canada [8], and Taiwan [9] and are considered indi-
cators of aggressive care at EOL. Because aggressive care at
EOL is inappropriate for the dying, these indicators can be
used to evaluate the quality of hospice care programs.
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Although hospice care is currently considered appro-
priate for terminally ill patients in Taiwan and has been
increasing for more than 20 years, it remains underuti-
lized. In Taiwan, the rate of patients with any type of
cancer who received hospice care during their final year
of life increased from 7.34 % in 2000 to 16.83 % in 2006
[10]; however, the overall prevalence remained low. Hos-
pice patients can receive care, such as emergency room
(ER) visits, hospital admission, and anticancer treatment,
if they require symptom relief. In Taiwan, hospice care
service models are delivered by hospital-based hospice
care units, which provide both inpatient and home care
services. To increase hospice care coverage, hospice
shared care is a new care model that has been used since
2005 to treat advanced cancer inpatients admitted to
non-hospice wards [11]. There are no independent hos-
pices in the community in Taiwan. Among patients re-
ceiving hospice care, 12.4 % receive it at home and
87.6 % receive it in a hospital [9]. Patients diagnosed
with advanced progressive cancers with a prognosis of
approximately 6-month survival are eligible for hospice
care. The assessment criteria applied in this study were
in accordance with Ministry of Health regulations. The
application of hospice care was assessed by the hospice
care team. If patients with terminal illnesses require hos-
pice services, they must be transferred to hospice care
wards; many patients or their families express a wish for
do-not-resuscitate orders.
In the United States and Canada, hospice care is mostly
home based. In Taiwan, although hospice services can be
delivered to patients in their homes, they are predomin-
antly provided in hospital hospice wards. Both forms of
hospice care are covered by Taiwan’s National Health In-
surance (NHI) program; therefore, patients do not need to
pay for this service. Previous studies have applied the care
QIs to evaluate EOL care for patients with any cancer type
[8, 12–14] or specifically lung [15], colorectal [16], and
breast [17] cancer; however, the findings have been incon-
sistent. For example, Saito et al. reported improvements
in all six QIs [15]. Dudgeon et al. reported a decrease in
the percentage of multiple ER visits and multiple hospital
admissions, but a nonsignificant decrease in the percent-
age of deaths in a hospital setting [12]. No study has eval-
uated EOL care for patients with terminal liver cancer,
which is a leading cause of cancer death in Taiwan [4].
In this study, we used claims date from the Taiwan
NHI Research Database (NHIRD) to evaluate the effect
of hospice care on the QIs of EOL care for terminal liver
cancer patients in Taiwan.
Methods
Data source and identification
Taiwan’s NHI program is a single-payer health insurance
system implemented in March 1995 and had a high
national coverage rate of 98.4 % in 2007 [18]. The
Taiwan NHIRD contains original claims data of nearly
all of Taiwan’s more than 23 million residents. In
Taiwan, all cancer patients are designated as having a
catastrophic illness. We first identified all patients with
catastrophic illness designations in Taiwan’s Longitu-
dinal Health Insurance Database 2000, a random and
systematic sample of one million NHI beneficiaries
from 2000 to 2011. We then used the claims data of
these patients to identify patients with primary liver
cancer, defined according to the International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes 155, 155.0, and 155.1. The patients
were further subcategorized according to the presence of
comorbid conditions, including hepatitis B virus (HBV)
(ICD-9-CM codes 070.20–070.23, 070.30–070.33, and
V0261) and hepatitis C virus (HCV) (ICD-9-CM codes
070.41, 070.44, 070.51, 070.54, and V0262). Other comor-
bid conditions were defined as in previous studies [19, 20].
Patients were excluded if they died at an age younger
than 20 years or had no definite death date, no insur-
ance claims during their final year of life, or inaccurate
(e.g., their death date was earlier than their diagnosis
date) or missing data.
QIs of EOL cancer care in the final month of life
The literature review revealed six widely accepted QIs of
cancer care in the final month of life [5, 9, 21, 22];
namely (1) receiving chemotherapy during the final
2 weeks of life, (2) having more than one ER visit during
the final month of life, (3) being admitted to a hospital
more than once during the final month of life, (4) being
admitted to an ICU during the final month of life, (5)
receiving CPR requiring intubation and mechanical ven-
tilation during the final month of life, and (6) dying in
acute care wards or hospice wards in the hospitals.
Death in the hospital was defined as a date of discharge
that was the same as the date of death [22]. Because
chemotherapy is not commonly used to treat patients
with liver cancer, the indicator of chemotherapy during
the final 2 weeks of life was changed to anticancer ther-
apies, including transarterial chemoembolization, hepatic
arterial infusion chemotherapy, percutaneous ethanol in-
jection, radiofrequency ablation, and radiotherapy in the
final month of life. Sorafenib, the target therapy for he-
patocellular carcinoma, was not included in this study
because it was not introduced to Taiwan until 2010, the
final year of our 10-year study period. These six QIs of
EOL care have been adopted by researchers from the
United States [5, 7], Canada [8], and Taiwan [9] and il-
lustrate the quality of care for patients with cancers in
the last month of life.
Hospice patients were defined as those with claims for
hospice care at least once between diagnosis and death,
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whereas non-hospice patients (non-H group) were those
without such claims. Hospice patients were further
divided into two groups according to whether the length
of hospice care was shorter (short-H group) or longer
(long-H group) than 1 month. Patients in the short-H
group received hospice care in the last month of life
and patients in the long-H group received hospice care
for longer than the last month of life. This classification
was also convenient for the analysis. Length of hospice
care was calculated from the date of first hospice
service until death.
The patients were further subcategorized according to
family socioeconomic status (SES) based on previous
studies [23,24]. A family earning less than NT$20,000
(approximately US$571), NT$20,000–40,000 (US$571–
1141), and more than NT$40,000 (US$1141) per month,
as listed in the claims data, was defined as having a low,
moderate, and high SES, respectively.
The Research Ethics Committee of Buddhist Dalin Tzu
Chi Hospital, Taiwan, reviewed and approved the protocol
of this study (No. B10301001). Because the NHIRD files
contain only de-identified secondary data, the review
board waived the requirement for informed consent.
Statistical analysis
Mean ± standard deviation (SD) and frequency (propor-
tions) were used to describe group characteristics. Cat-
egorical variables were analyzed using the chi-square
test, and continuous variables were compared using the
t test or the Wilcoxon rank-sum test, as appropriate.
The Kaplan–Meier method was adopted for survival data
analyses. Multiple logistic regression analysis with a step-
wise variable selection procedure was conducted to com-
pute adjusted odds ratios (ORs) and 95 % confidence
intervals (CIs) for the association among the QIs of EOL
cancer care. Generalized additive models were fitted to de-
tect potential nonlinear effects of continuous Licensecov-
ariates and identify an appropriate cutoff point for
discretizing continuous predictors, such as age, during
stepwise variable selection. Area under the curve (AUC)
analysis for receiver operating characteristic curves was
performed. We assumed that an AUC of ≥0.7 indicated an
acceptable level of discrimination for the fitted logistic re-
gression model. The goodness of fit of the logistic regres-
sion model was assessed using the Hosmer–Lemeshow
test. Statistical analysis was performed using R, Version
2.15.1 (The R Foundation). A two-sided p < 0.05 was con-
sidered significant.
Results
After exclusion, we observed that 3092 adult patients
(2216 men, 876 women; ratio = 2.5:1) died of liver can-
cer between 2000 and 2011. Figure 1 shows the enroll-
ment flow chart. Of the patients, 137 (4.4 %) were in
the long-H group, 325 (10.5 %) were in the short-H
group, and 2630 (85.1 %) were in the non-H group. The
mean ± SD survival probabilities (years) after diagnosis
in the long-H, short-H, and non-H groups were 1.60 ±
0.17, 1.52 ± 0.11, and 1.40 ± 0.04 years, respectively.
There was no significant difference in survival probabil-
ity among the three groups (log-rank test p = 0.212)
(Fig. 2). The mean ± SD (median) days from hospice en-
rollment to death were 36.37 ± 66.43 (19.00) days. The
non-H group was significantly younger than both hos-
pice subgroups. Both hospice subgroups were less likely
to have esophageal bleeding and hemodialysis, but
more likely to have diabetes, hypertension, and more
hospital stays during the final month of life compared
with the non-H group. All of these trends were signifi-
cant (Table 1). We recorded the number of comorbidi-
ties as 0, 1, 2, 3, or >3. Comorbidities included diabetes,
hypertension, stroke, liver cirrhosis, esophageal varices
bleeding, portal hypertension, ascites, spontaneous bac-
terial peritonitis, hepatic encephalopathy, hepatorenal
syndrome, hemodialysis, and chronic kidney diseases.
Analysis showed no significant differences between
non-H, short-H, and long-H groups among patients
with comorbidities. However, we found a significantly
higher proportion of patients with metastasis of ad-
vanced liver cancer in the long-H group than in the
short-H and non-H groups (p < 0.001).
The main outcome measures in this study were the six
QIs of EOL cancer care. Compared with patients in the
long-H and short-H groups, a higher proportion of pa-
tients in the non-H group were admitted to an ICU
(20.8 %) or received CPR (22.6 %) compared with
patients in the long-H group (7.3 % and 6.6 %, respect-
ively) and the short-H group (6.8 % and 2.8 %, respect-
ively, ps < 0.001). A lower proportion of patients in the
long-H group had more than one ER visit, compared
with both those in the non-H and short-H groups (2.9 %
vs. 4.6 %, 8.9 %, respectively, p = 0.003). A lower propor-
tion of patients in the non-H group were admitted to a
hospital more than once compared with those in the
short-H and long-H groups (21.1 % vs. 31.7 %, 26.3 %,
respectively, p < 0.001). Regarding the place of death, we
found that fewer patients in the long-H group died in
the hospice ward compared with patients in the short-H
group (59.1 % and 68.0 %, respectively). We observed no
significant difference regarding treatment with antican-
cer therapy during the final month of life among the
three groups (p = 0.362). Further subanalysis revealed
that more patients in the long-H group received radio-
therapy compared with those in the short-H and non-H
groups during this period (9.5 % vs. 7.7 %, 4.5 % respect-
ively, p = 0.004) (Table 2).
Multiple logistic regressions were performed to exam-
ine the QI risk factors. The long-H and short-H groups
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had a significantly lower risk of ICU admission (OR = 0.25,
95 % CI: 0.12–0.47 and OR = 0.26, 95 % CI: 0.16–0.40,
respectively, p < 0.001) and receiving CPR (OR = 0.21, 95 %
CI: 0.10–0.39 and OR = 0.09, 95 % CI: 0.04–0.17, respect-
ively, p < 0.001) compared with the non-H group after ad-
justments. However, the short-H group had a higher risk of
more than one ER visit, more than one admission, and
death in the hospital (OR = 1.97, 95 % CI: 1.25–3.02, OR =
1.56, 95 % CI: 1.20–2.03, and OR = 2.42, 95 % CI: 1.86–
3.17, respectively), whereas the long-H group had reduced
risks (OR = 0.68, 95 % CI: 0.20–1.67, OR = 1.07, 95 % CI:
0.70–1.60, and OR = 1.29, 95 % CI: 0.87–1.94) compared
with the non-H group (Table 3).
We combined all the indicators and found that 2043
(66.1 %) patients had one or more of the six indicators.
The short-H group had a higher risk of exhibiting one or
more of the indicators compared with the non-H group
(OR = 1.56, 95 % CI: 1.13–2.18, p = 0.008), whereas there
was no significant difference between the long-H group
and the non-H group (OR = 0.99, 95 % CI: 0.62–1.60,
p = 0.954). All AUCs of these models exceeded 0.7, and
the final model yielded the highest R2 (0.418) and AUC
values (0.833) (Table 3 & Fig. 3). The complete models
are listed in Additional file 1.
Discussion
This study determined that hospice care, regardless of
subgroup, reduced the likelihood of a patient being ad-
mitted to an ICU by approximately 75 % (long-H vs.
non-H group, OR = 0.25; short-H vs. non-H group,
Fig. 1 Study flow chart. Abbreviations: ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; CIC, catastrophic
illness certificate
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OR = 0.26, p < 0.001) or receiving CPR by 80 %–90 %
(long-H vs. non-H group, OR = 0.21; short-H vs. non-
H group, 0.09, p < 0.001). However, the short-H group
was 97 % more likely to have more than one ER visit
(OR = 1.97, p = 0.003), and 56 % more likely to have more
than one hospital admission (OR = 1.56, p = 0.001) com-
pared with the non-H group. These three risks were lower
for patients who received hospice care for more than
1 month. In addition, no differences in the three risks
were observed between the long-H and non-H groups
(OR = 0.68, p = 0.453; OR = 1.07, p = 0.762; and OR = 1.29,
p = 0.204, respectively) and there were no differences re-
garding use of anticancer therapy among the three groups.
To the best of our knowledge, the results of this study
are consistent with those of previous studies: that hos-
pice care reduces the risk of admission to ICUs and use
of CPR [8, 12–15]. Saito et al., who investigated elderly
hospice patients with non–small-cell lung cancer [15], and
Gonsalves et al., who examined advanced cancer patients
in hospice care [14], have reported improvement in all six
QIs compared with non-hospice patients. Obermeyer et al.
reported that elderly hospice patients with cancer had
fewer hospitalizations, ICU admissions, CPR treatments,
and deaths in hospital than those not receiving hospice
care; however, the researchers excluded patients receiving
chemotherapy [13]. Barbera et al. reported fewer ER visits,
ICU visits, and chemotherapy treatments in people receiv-
ing hospice care); however, they did not include the other
three QIs [8]. One previous study indicated that Taiwanese
cancer patients receiving hospital-based hospice care
were significantly less likely to be intubated or require
a mechanical ventilator [25].
Liver cancer is the third most common cause of death
among cancers worldwide and has a high fatality rate
(overall ratio of mortality to incidence: 0.93) [26]. It is
the leading cause of cancer death in Taiwan (18.3 % in
2013) [27]. In this study, we found that patients with ad-
vanced liver cancer who were not receiving hospice care
were likely to use ICU care (20.8 %) and receive CPR
(22.6 %) in the last month of life, compared with patients
who had received a short duration (6.8 % and 2.8 %, re-
spectively) and long duration (7.3 % and 6.6 %, respect-
ively) of hospice care. This may be because the most
common causes of liver cancer death were liver-cancer-
related or hepatic failure, followed by esophageal varices
with bleeding, infections, and renal failure [28], which
might incentivize patients to receive intensive care to
control the progress or the complications of disease.
However, patients who received hospice care required
less ICU care and less CPR.
Hospice care is delivered mainly as an inpatient ser-
vice and less as a home-based service in Taiwan. Hospice
patients with advanced cancer might frequently visit ERs
or be admitted to hospitals to receive services that re-
lieve suffering. We found that patients in the short-H
group had more ER visits and hospitalizations than did
those in the non-H and long-H groups. There are several
possible reasons for this pattern. First, the short-H group
might have required more medical assistance for symp-
tom control; second, the patients’ symptoms or their in-
formal hospice caregivers’ skills [29] might have been
improved after long-term hospice care; third, the com-
munication between patients/their families and nurses
might have improved after long-term hospice care [30].
Dudgeon et al., who enrolled patients with all types of
cancer in a study assessing a palliative care integration
strategy, reported fewer ER visits and hospital admis-
sions but no significant decreases in the percentage of
deaths in hospital; however, they did not examine the
other three QIs [12]. A previous study investigating why
Taiwanese cancer patients preferred to stay in hospital
suggested that a more effective referral system be estab-
lished and that home-based hospice services be pro-
vided [31]. Education could have a significant effect on
EOL care [32]. Our findings suggest that EOL cancer
care in Taiwan might be optimized if health care pol-
icies promoted early hospice referral programs (longer
than 1 month) and education for preparing patients
and families for death.
Despite increases in the use of palliative and hospice
care in elderly patients with terminal illness, ethnic dis-
parities persist [33]. Therefore, hospice care teams who
understand cultural differences between Chinese and
Western societies might improve EOL quality care. In
traditional Chinese culture, death is a sensitive issue and
people avoid mentioning it, as to do so is considered
Fig. 2 The Kaplan–Meier estimates of survival curves for advanced
liver cancer patients stratified by hospice care. Patients were grouped
according to those who received hospice care for longer than 1 month
(long-H group), shorter than 1 month (short-H group), and not at all
(non-H group)
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Table 1 Demographic characteristics of patients with liver cancer
Variable Total Non-H group Short-H group Long-H group p-value p-value for trend test
N (%) 3092(100 %) 2630(85.1 %) 325(10.5 %) 137(4.4 %)
Gender 0.019
female 876(28.3 %) 737(28.0 %) 86(26.5 %) 53(38.7 %) 0.072
male 2216(71.7 %) 1893(72.0 %) 239(73.5 %) 84(61.3 %) 0.072
Age 65.6 ± 13.37 65.9 ± 13.42 67.70 ± 12.42 67.50 ± 13.85 0.001 0.001
Survival (years) 1.43 ± 0.03 1.40 ± 0.04 1.52 ± 0.11 1.60 ± 0.17 0.212 0.162
Diabetes 446(14.4 %) 360(13.7 %) 54(16.6 %) 32(23.4 %) 0.004 0.001
Hypertension 2875(93.0 %) 2414(91.8 %) 324(99.7 %) 137(100 %) <0.001 <0.001
Stroke 209(6.8 %) 169(6.4 %) 27(8.3 %) 13(9.5 %) 0.190 0.070
Liver cirrhosis 2108(68.2 %) 1794(68.2 %) 226(69.5 %) 88(64.2 %) 0.532 0.619
Esophageal varices bleeding 420(13.6 %) 381(14.5 %) 29(8.9 %) 10(7.3 %) 0.002 0.001
Portal hypertension 43(1.4 %) 37(1.4 %) 5(1.5 %) 1(0.7 %) 0.782 0.680
Ascites 908(29.4 %) 765(29.1 %) 102(31.4 %) 41(29.9 %) 0.685 0.518
SBP 23.8(7.7 %) 206(7.8 %) 24(7.4 %) 8(5.8 %) 0.678 0.405
Hepatic encephalopathy 766(24.8 %) 638(24.3 %) 92(28.3 %) 36(26.3 %) 0.257 0.189
Hepatorenal syndrome 99(3.2 %) 91(3.5 %) 4(1.2 %) 4(2.9 %) 0.076 0.138
Hemodialysis 147(4.8 %) 138(5.2 %) 6(1.8 %) 3(2.2 %) 0.001 0.005
CKD 183(5.9 %) 151(5.7 %) 21(6.5 %) 11(8.0 %) 0.431 0.245
Comorbidity of above
No. of comorbidities = 0 141(4.6 %) 140(5.3 %) 1(0.3 %) 0 <0.001 <0.001
No. of comorbidities = 1 549(17.8 %) 473(18.0 %) 49(15.1 %) 27(19.7 %) 0.349 0.750
No. of comorbidities = 2 765(24.7 %) 630(24.0 %) 101(31.1 %) 34(24.8 %) 0.022 0.080
No. of comorbidities = 3 728(23.5 %) 613(23.3 %) 80(24.6 %) 35(25.5 %) 0.722 0.442
No. of comorbidities > 3 909(29.4 %) 774(29.4 %) 94(28.9 %) 41(29.9 %) 0.969 0.994
Metastasis 974(31.5 %) 781(29.7 %) 130(40.0 %) 63(46.0 %) <0.001 <0.001
HBV 1079(34.9 %) 914(34.8 %) 123(37.8 %) 42(30.7 %) 0.308 0.877
HCV 832(26.9 %) 690(26.2 %) 100(30.8 %) 42(30.7 %) 0.129 0.061
CCI 3.69 ± 2.45 3.68 ± 2.40 3.68 ± 2.74 3.96 ± 2.80 0.284 0.284
SES
LES 2080(67.3 %) 1764(67.1 %) 222(68.3 %) 94(68.6 %) 0.869 0.585
MES 800(25.9 %) 682(25.9 %) 83(25.5 %) 35(25.5 %) 0.996 0.746
HES 212(6.9 %) 184(7.0 %) 20(6.2 %) 8(5.8 %) 0.836 0.466
Urbanization level
Urban 1513(48.9 %) 1292(49.1 %) 149(45.8 %) 72(52.6 %) 0.374 0.994
Suburban 1092(35.3 %) 937(35.6 %) 111(34.2 %) 44(32.1 %) 0.651 0.340
Rural 487(15.8 %) 401(15.2 %) 65(20.0 %) 21(15.3 %) 0.090 0.207
Teaching hospitala 1879(62.3 %) 1626(63.5 %) 169(53.5 %) 84(61.3 %) 0.003 0.021
Admission daysb 13.7 ± 10.8 13.0 ± 10.9 16.5 ± 8.98 18.8 ± 11.3 <0.001 <0.001
an = 3015
bAdmission days: mean admission days in the last month
Abbreviations: Non-H group, patients who did not receive hospice care; Long-H group, patients who received hospice care for longer than 1 month; Short-H
group, patients who received hospice care for a period shorter than 1 month; SBP, spontaneous bacterial peritonitis; CKD, chronic kidney disease; HBV, hepatitis B
virus; HCV, hepatitis C virus; CCI, Charlson comorbidity index; SES, socioeconomic status; LES, low socioeconomic status; MES, moderate socioeconomic status; HES,
high socioeconomic status
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sacrilegious [34]. This might explain why there was more
than one admission to an acute care hospital in the last
month of life for patients in the non-H group (21.1 %),
and more than one hospice ward admission in the last
month of life for patients in the short-H and long-H
groups (31.7 % and 26.3 %, respectively). “The fallen
leaves can return to their roots” is an important trad-
itional Chinese religious concept [35]. Therefore, dying
at home has a special meaning for patients and their
families in Taiwan. Dying patients in Taiwan were com-
monly discharged “against medical advice” from the
hospital and often with artificial respiratory support
(e.g., nasal cannula) to allow their families to keep the
patient “alive” long enough to enable them to die at
home [9]. Accordingly, if the date of discharge for the
last admission was the same as the date of death [22],
the patients were recognized as dying in the acute care
ward or in the hospice ward (if they had been admitted
to a hospice).
Although many experts recommend a hospice stay of
at least 3 months to provide standard hospice services
[36], the average length of hospice stay is about 1 month
in the United States [37]. One previous study reported
that late hospice referral could increase the risk of a
major depressive disorder during the first year of be-
reavement [38], result in lower reported satisfaction with
hospice services by family members [39], and be related
to the quality of patient care received [40]. In a multi-
center survey, only 1.5 % of families assessed the timing
of home-based hospice referral as early and 42.0 %
assessed it as late [41]. Patients who are referred to hos-
pice care early in their disease process can benefit more
easily from this care, which may improve patients’ qual-
ity of life, patient and family satisfaction, and the cost
Table 2 Comparison of quality indicators of end-of-life cancer care in the last month
Variables Total Non-H group Short-H group Long-H group p-value p-value for trend test
N (%) 3092(100 %) 2630(85.1 %) 325(10.5 %) 137(4.4 %)
ICU admission 580(18.8 %) 548(20.8 %) 22(6.8 %) 10(7.3 %) <0.001 <0.001
CPR 613(19.8 %) 595(22.6 %) 9(2.8 %) 9(6.6 %) <0.001 <0.001
More than one ER visit 153(4.9 %) 120(4.6 %) 29(8.9 %) 4(2.9 %) 0.003 0.217
More than one admission(>1) 695(22.5 %) 556(21.1 %) 103(31.7 %) 36(26.3 %) <0.001 <0.001
Death in acute care wards 1182(38.2 %) 1182(44.9 %) 0 0 - -
Death in hospice ward 302(9.8 %) 0 221(68.0 %) 81(59.1 %) - -
Anti-cancer therapy
Chemotherapy 61(2.0 %) 49(1.9 %) 9(2.8 %) 3(2.2 %) 0.459 0.406
TACE 128(4.1 %) 117(4.4 %) 7(2.2 %) 4(2.9 %) 0.117 0.074
HAIC 37(1.2 %) 30(1.1 %) 6(1.8 %) 1(0.7 %) 0.496 0.781
PEI 10(0.3 %) 10(0.4 %) 0 0 0.755 0.215
RFA 11(0.4 %) 11(0.4 %) 0 0 0.771 0.193
Radiotherapy 157(5.1 %) 119(4.5 %) 25(7.7 %) 13(9.5 %) 0.004 0.001
Ever anti-cancer therapy 348(11.3 %) 288(11.0 %) 41(12.6 %) 19(13.9 %) 0.362 0.183
Abbreviations: Non-H group, patients who did not receive hospice care; Long-H group, patients who received hospice care for longer than 1 month; Short-H
group, patients who received hospice care for a period shorter than 1 month; ICU, intensive care unit; CPR, cardiopulmonary resuscitation; ER, emergency room;
TACE, transarterial chemoembolizations; HAIC, hepatic arterial infusion chemotherapy; PEI, percutaneous ethanol injection; RFA: radiofrequency ablation
Table 3 Factors associated with quality indicators of end-of-life care among patients with liver cancer




More thanone admission Death in
hospital
One or more of
aboveindicators










































R2 0.159 0.142 0.124 0.110 0.142 0.295 0.418
Figures are odds ratios (confidence intervals) and associated p values
Abbreviations: Non-H group, patients who did not receive hospice care; Long-H group, patients who received hospice care for longer than 1 month; Short-H
group, patients who received hospice care for a period shorter than 1 month; ICU, intensive care unit; CPR, cardiopulmonary resuscitation; AUC, area under the
curve. All models were adjusted according to the significant variables shown in Tables 1 and 2. The full models are in Additional file 1
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effectiveness of treatment [42]. The barriers to early
referral are related to physician and patient/family atti-
tudes as well as the reimbursement structure itself.
Physician-related barriers include a reluctance to discuss
hospice care because of fears about the patient’s/family’s
reaction, difficulty in survival prediction, feelings of pro-
fessional failure, and loss of control [43–46]. Patient-
related barriers include denial of health status, a desire
to exhaust all treatment options, a negative perception of
hospice care, and patient demographics [42,47]. Another
challenging issue is the prediction of survival for patients
with advanced cancer. To date, clinician prediction of sur-
vival is one of the most practical and commonly used tem-
poral approaches for prognosis estimation in spite of its
tendency to overestimate survival time [48,49]. Clinicians
specialized in palliative care need to be proficient at prog-
nosis to provide the best EOL care for their patients.
Accurate survival prediction allows patients and their fam-
ilies to develop insight into their dying and thereby set
realistic priorities and expectations of care.
Limitations
This study has some limitations. One limitation is the pos-
sibility of misclassification bias because of the inaccuracy
of some of the variables used, including the calculation of
the comorbidity score. Another limitation is the possibility
of selection bias, which might have occurred because the
participant allocation was not randomized. Moreover, the
rate of cirrhosis and its complications, such as esophageal
bleeding and ascites, might have been underestimated be-
cause our data were obtained from claims data and not
medical records. Furthermore, this reliance on claims data
made it impossible to collect information on clinical
symptoms and signs, patient or family preferences, or do-
not-resuscitate designations. In addition, patient or
family decision making may have influenced some of
the outcomes.
Conclusion
There was no significant difference in survival probability
between the hospice groups. Both hospice groups were
less likely to require ICU admissions or CPR during the
final month of life. However, the short-H group exhibited
a higher risk of more than one ER visit, and more than
one hospital admission, compared with the non-H and
long-H groups. We conclude that EOL cancer care in
Taiwan might be improved by policies encouraging early
hospice referral programs (longer than 1 month) and
more realistic education that prepares patients and their
families for imminent death.
Additional file
Additional file 1: Factors associated with quality indicators of end-
of-life care among patients with liver cancer. Figures are odds ratios
(confidence intervals) and associated p values. Abbreviations: Non-H
group, patients who did not receive hospice care; Long-H group, patients
who received hospice care for longer than 1 month; Short-H group, patients
who received hospice care for a period shorter than 1 month; ICU, intensive
care unit; CPR, cardiopulmonary resuscitation; ER, emergency room; HBV,
hepatitis B virus; HCV, hepatitis C virus; SBP, spontaneous bacterial peritonitis;
CKD, chronic kidney disease; LES, low socioeconomic status; MES, moderate
socioeconomic status; HES, high socioeconomic status; PPV, positive
predictive value; NPV, negative predictive value; AUC, area under the
curve; HL, Hosmer–Lemeshow. (DOCX 18 kb)
Abbreviations
AUC: area under the receiver operating characteristic curve; CCI: Charlson
comorbidity index; CIC: catastrophic illness certificate; CKD: chronic kidney
disease; CPR: cardiopulmonary resuscitation; DNR: Do not resuscitate; EOL: end-
of-life; ER: emergency room; HAIC: hepatic arterial infusion chemotherapy;
HBV: hepatitis B virus; HCV: hepatitis C virus; ICD-9-CM: International
Classification of Diseases, Ninth Revision, Clinical Modification; ICU: intensive
care unit; NHI: National Health Insurance; NHIRD: National Health Insurance
Research Database; PEI: percutaneous ethanol injection; QI: quality indicator;
RFA: radiofrequency ablation; SES: socioeconomic status; TACE: transarterial
chemoembolization.
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AUC was 0.833 for the prediction of receiving one or more indicators
among patients with advanced liver cancer in their last month of life
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